Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial
Publication date: October 2026 Source: The Lancet Infectious Diseases, Volume 26, Issue 10 Author(s): Caitlin Pley, David J Jeffries, Ebrima Kanteh, Julia Strandmark, Aru Kumba Baldeh, Mam Nabou Leigh, Peter Ndow, Ed Clarke, Beate Kampmann
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial. // The Lancet Infectious Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S1473309926001933?dgcid=rss_sd_all
Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial. The Lancet Infectious Diseases. https://www.sciencedirect.com/science/article/pii/S1473309926001933?dgcid=rss_sd_all
“Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial.” The Lancet Infectious Diseases.
@article{article101644,
title = {Yellow fever vaccination in healthy Gambian children of different ages to establish safety and immunogenicity of a booster dose: a open-label, non-randomised, single-site, phase 3 vaccine trial},
journal = {The Lancet Infectious Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S1473309926001933?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...